GlassScriptPhysician profile
Neil S Schaul
NPI 1497779565
$2,039.28
in general payments reported to CMS, 2019-2025
13 companies · $20.03 in 2025
The $20.03 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $130 · 2021: $358 · 2022: $521 · 2023: $180 · 2024: $107 · 2025: $20.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $600.04 | 2019-2023 | |
| Sk Life Science, INC. | $449.79 | 2021-2025 | |
| Ucb, INC. | $338.50 | 2019-2023 | Fintepla |
| Sunovion Pharmaceuticals INC. | $149.92 | 2019-2022 | |
| Greenwich Biosciences, INC. | $118.11 | 2019-2021 | |
| Aquestive Therapeutics, INC. | $111.12 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $87.70 | 2019 | |
| Livanova USA, INC. | $47.40 | 2019-2022 | |
| Zogenix INC. | $46.56 | 2021 | |
| Neurelis, INC. | $39.39 | 2022-2024 | Valtoco |
| Sumitomo Pharma America, INC. | $17.57 | 2023 | Aptiom |
| Jazz Pharmaceuticals INC. | $17.09 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $16.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Schaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.